Perceptive Xontogeny Venture Fund Leads $35M Investment in AsclepiX Therapeutics

Choate represented Perceptive Xontogeny Venture Fund as the lead investor in the $35M Series A investment into AsclepiX Therapeutics, which is currently developing therapies for the treatment of diseases of the eye using novel peptides with the power to inhibit proven key disease pathways. The company’s lead compound, AXT107, is in development as a treatment for three eye disorders – diabetic macular edema, the “wet” form of age-related macular degeneration, and retinal vein occlusion – and a clinical trial could start by the end of 2020. AsclepiX also has three earlier-stage candidates in development for treating solid cancer tumors.